Cargando…

Letter to the Editor From Sävendahl et al.: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”

Detalles Bibliográficos
Autores principales:	Sävendahl, Lars, Battelino, Tadej, Brod, Meryl, Højby Rasmussen, Michael, Juul Kildemoes, Rasmus, Saenger, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Online Only Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8764219/ https://www.ncbi.nlm.nih.gov/pubmed/34626473 http://dx.doi.org/10.1210/clinem/dgab736

Ejemplares similares

Response to Letter to the Editor From L. Sävendahl et al: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Response to Letter to the Editor From Malozowski: “Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial”
por: Thornton, Paul S, et al.
Publicado: (2021)

Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial
por: Sävendahl, Lars, et al.
Publicado: (2020)

Weekly Lonapegsomatropin in Treatment–Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial
por: Thornton, Paul S, et al.
Publicado: (2021)

Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2021)

Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3
por: Sävendahl, Lars, et al.
Publicado: (2023)

Switching to Weekly Lonapegsomatropin from Daily Somatropin in Children with Growth Hormone Deficiency: The fliGHt Trial
por: Maniatis, Aristides K., et al.
Publicado: (2022)

RF26 | PMON334 Once-Weekly Somapacitan in Growth Hormone Deficiency: 4-Year Efficacy and Safety Results from REAL 3, a Randomised Controlled Phase 2 Trial
por: Savendahl, Lars, et al.
Publicado: (2022)

SUN-247 Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Efficacy and Safety Results of a Randomized, Open-Label, Controlled Phase 2 Trial (REAL 3)
por: Savendahl, Lars, et al.
Publicado: (2019)

Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results
por: Maniatis, Aristides K, et al.
Publicado: (2022)

Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan
por: Juul Kildemoes, Rasmus, et al.
Publicado: (2020)

Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021)

SAT-091 First Report of Disease-Specific Patient-Reported Outcomes from a Randomized Phase 2 Trial of Once-Weekly Somapacitan vs Daily GH in Children with GHD
por: Brod, Meryl, et al.
Publicado: (2020)

THU073 Somapacitan Administered Subcutaneously At 5 mg/1.5 mL Or 10 mg/1.5 mL Strengths Yields Clinically Similar PK And IGF-I Profiles In Healthy Participants
por: Rasmussen, Michael Højby, et al.
Publicado: (2023)

Dose–exposure–IGF-I response of once-weekly somapacitan in adults with GH deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2022)

Efficacy and Safety of up to 2 Years of Treatment With TransCon hGH (Lonapegsomatropin) in Treatment-Naïve and Treatment-Experienced Children With Growth Hormone Deficiency
por: Maniatis, Aristides K, et al.
Publicado: (2021)

SUN-248 Growth Hormone Deficiency (GHD): Assessing Burden of Treatment in Children and Adolescents
por: Brod, Meryl, et al.
Publicado: (2019)

Design of the ForesiGHt Trial: A Multicenter, Randomized, Placebo- and Active-Controlled Trial to Compare Once-Weekly TransCon hGH (lonapegsomatropin) to Placebo and Daily Somatropin in Adults With Growth Hormone Deficiency (GHD)
por: Fleseriu, Maria, et al.
Publicado: (2021)

SAT-LB12 Once-Weekly Somapacitan vs Daily Growth Hormone in Growth Hormone Deficiency: 2-Year Safety Results From Real 3, a Randomized Phase 2 Trial
por: Savendahl, Lars S, et al.
Publicado: (2020)

Impact of adult growth hormone deficiency on daily functioning and well-being
por: Brod, Meryl, et al.
Publicado: (2014)

THU174 Model-Based Analysis Of IGF-I Response, Dosing, And Monitoring For Once-Weekly Somapacitan In Children With GH Deficiency
por: Kildemoes, Rasmus Juul, et al.
Publicado: (2023)

Response to Letter to the Editor From Chatelain et al: “Weekly Somapacitan Is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial”
por: Miller, Bradley S, et al.
Publicado: (2023)

RF26 | PMON335 Once-Weekly Somapacitan Versus Daily Growth Hormone in Children Born Small for Gestational Age: Results From a Randomized Phase 2 Trial
por: Juul, Anders, et al.
Publicado: (2022)

Understanding Treatment Burden for Children Treated for Growth Hormone Deficiency
por: Brod, Meryl, et al.
Publicado: (2017)

Understanding burden of illness for child growth hormone deficiency
por: Brod, Meryl, et al.
Publicado: (2017)

THU173 Subanalysis By Tanner Stage In Phase 3 Trials In Children And Adolescents With Growth Hormone Deficiency Treated With Lonapegsomatropin
por: Hofman, Paul, et al.
Publicado: (2023)

Iron affects localization of Ght5 in fission yeast
por: Akyüz, Sevim Nur, et al.
Publicado: (2023)

Psychometric Validation of the Growth Hormone Deficiency-Child Impact Measure (GHD-CIM)
por: Brod, Meryl, et al.
Publicado: (2021)

InSiGHT leads in the implementation of the Human Variome Project
por: Macrae, Finlay, et al.
Publicado: (2011)

Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
por: Brod, Meryl, et al.
Publicado: (2018)

Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
por: Brod, Meryl, et al.
Publicado: (2022)

Weekly Somapacitan is Effective and Well Tolerated in Children With GH Deficiency: The Randomized Phase 3 REAL4 Trial
por: Miller, Bradley S, et al.
Publicado: (2022)

RF14 | LBMON195 Once-weekly Somapacitan Is Effective And Well Tolerated In Children With GH Deficiency: A Randomized Phase 3 Trial
por: Miller, Bradley, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials
por: Juul, Rasmus Vestergaard, et al.
Publicado: (2018)

RF26 | PMON332 Safety and Efficacy of Treatment with Lonapegsomatropin in Children with Growth Hormone Deficiency at Week 130 in the enliGHten Trial
por: Saenger, Paul, et al.
Publicado: (2022)

The InSiGHT approach to classification of mismatch repair gene variants
por: Plazzer, JP
Publicado: (2012)

InSiGHT 2022 Abstract Publishing and Best Abstract Awards
Publicado: (2022)

Average IGF-1 Prediction for Once-Weekly Lonapegsomatropin in Children With Growth Hormone Deficiency
por: Lin, Zhengning, et al.
Publicado: (2021)

Once-weekly Somapacitan is Effective and Well Tolerated in Adults with GH Deficiency: A Randomized Phase 3 Trial
por: Johannsson, Gudmundur, et al.
Publicado: (2020)

Innovation and entrepreneurship in the HEI sector
por: Ferreira, João
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4lous15i2gcujl2a5c6pu1u0cj